Man Group PLC T Scan Therapeutics, Inc. Transaction History

Man Group PLC

  • $36 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$5.85 - $9.51 $343,324 - $558,122
-58,688 Reduced 75.88%
18,651 $109,000
Q1 2024

May 15, 2024
BUY
$4.89 - $8.3 $131,682 - $223,510
26,929 Added 53.42%
77,339 $614,000
Q4 2023

Feb 14, 2024
BUY
$2.66 - $6.76 $134,090 - $340,771
50,410 New
50,410 $293,000

Others Institutions Holding TCRX

# of Institutions
89
Shares Held
41.8M
Call Options Held
0
Put Options Held
0
View Full List

About TScan Therapeutics, Inc.

TCRX Quotes by TradingView
  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $57.9M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email